MedeliX
Start asking

ixekizumab

Taltz · ATC code L04AC13

Also known as: İksekizumab

Key facts
Active substance
ixekizumab
Drug class
Immunosuppressive drug
ATC code
L04AC13
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Taltz 40 mg solution for injection in pre-filled syringe / Taltz 80 mg solution for injection in pre-filled syringe · Taltz 80 mg solution for injection in pre-filled pen
Marketing authorisation holder
Eli Lilly and Company (Ireland) Limited
Information as of
2026-10-28

Key facts

Ixekizumab is a monoclonal antibody against interleukin 17A. It is used for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis and certain forms of juvenile idiopathic arthritis.

What it is used for

  • Moderate to severe plaque psoriasis in adults and in children from 6 years with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy.
  • Active psoriatic arthritis in adults with inadequate response or intolerance to DMARDs, alone or with methotrexate.
  • Active ankylosing spondylitis and active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults.
  • Active juvenile psoriatic arthritis and enthesitis-related arthritis from 6 years of age and at least 25 kg, alone or with methotrexate.

Dosing

  • Taltz (40 mg/80 mg pre-filled syringe, 80 mg pre-filled pen), adult plaque psoriasis: 160 mg subcutaneously at week 0, then 80 mg at weeks 2, 4, 6, 8, 10 and 12, then 80 mg every 4 weeks.
  • Psoriatic arthritis and axial spondyloarthritis: 160 mg at week 0, then 80 mg every 4 weeks; with concomitant moderate to severe plaque psoriasis, as for plaque psoriasis.
  • Children from 6 years (plaque psoriasis, juvenile arthritis): greater than 50 kg starting dose 160 mg, then 80 mg every 4 weeks; 25 to 50 kg starting dose 80 mg, then 40 mg every 4 weeks. Not recommended below 25 kg.
  • Consider discontinuation if there is no response after 16 to 20 weeks.

Contraindications

  • Serious hypersensitivity to the active substance or to any of the excipients.
  • Clinically important active infections (e.g. active tuberculosis).

Important warnings

  • Increased rate of infections (e.g. upper respiratory tract infection, oral candidiasis, conjunctivitis, tinea); discontinue for serious infection. Consider anti-TB therapy before starting in latent TB.
  • Serious hypersensitivity reactions including anaphylaxis and angioedema, rarely late (10-14 days after injection).
  • New or worsening inflammatory bowel disease (Crohn's disease, ulcerative colitis); not recommended in IBD.
  • Do not use with live vaccines.
  • Record the name and batch number of the biological product.

Side effects

  • Most frequent: injection site reactions (15.5 %) and upper respiratory tract infections (16.4 %, mostly nasopharyngitis).
  • Common: tinea infection, herpes simplex, oropharyngeal pain, nausea.
  • Uncommon: inflammatory bowel disease, urticaria, rash, eczema.

Interactions

  • Safety with other immunomodulators or phototherapy not evaluated in plaque psoriasis; no live vaccines.
  • No clinically significant impact on CYP450 substrates; clearance not affected by corticosteroids, NSAIDs, sulfasalazine or methotrexate.

Pregnancy and breastfeeding

  • Women of childbearing potential should use effective contraception during and for at least 10 weeks after treatment; preferably avoid during pregnancy.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • TaltzEli Lilly and Company (Ireland) Limited · EMEA/H/C/003943

Source: European Medicines Agency (EMA), product information

Turkey

  • CopellorLİLLY İLAÇ TİC. LTD. ŞTİ. · 6 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Taltz
Liechtenstein
Taltz
Norway
Taltz

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Taltz – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf
  2. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
  3. Wikidata (CC0): ATC L04AC.

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.